TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26576750

Group type: EXPERIMENTAL
Intervention: Erythropoietin 500 IU·kg(‐1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 66
Study: 24993838

Group type: EXPERIMENTAL
Intervention: Gentamicin collagen implant (GCI)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no GCI)
Number of subjects: 171
Study: 22421244

Group type: COMPARATOR
Intervention: Standard therapy (amphotericin B 1 mg/kg per day and 5FC 100 mg/kg per day for 2 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IFNγ two doses (standard therapy plus IFNγ1b 100 μg on days 1 and 3)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IFNγ six doses (standard therapy plus IFNγ1b 100 μg on days 1, 3, 5, 8, 10, and 12)
Number of subjects: 88
Study: 21054874

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (exact dosage and duration not specified)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Screening question responses (no, yes, unsure)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Mean number of risk factors
Number of subjects: 1053
Study: 17991308

Group type: EXPERIMENTAL
Intervention: BSPCI delivering 258 microg of ET
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sublingual ET (2 mg tablet)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BSPCI delivering 129 microg of ET
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metered-dose inhaler delivering 2052 microg of ET
Number of subjects: 23
Study: 16305008

Group type: EXPERIMENTAL
Intervention: Colgate Simply White dentifrice (CSW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Whitening (CTW)
Number of subjects: 0
Study: 11865557

Group type: EXPERIMENTAL
Intervention: Antipyretic treatment during febrile episodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral diazepam as intermittent prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous anticonvulsant treatment
Number of subjects: 0
Study: 8060802

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study: 3111166

Group type: EXPERIMENTAL
Intervention: 5% glucose intravenous infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10% glucose intravenous infusion
Number of subjects: 24
Study: 29189337

Group type: EXPERIMENTAL
Intervention: Continuous endurance training (CET)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Strength endurance training (SET)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Interval endurance training (IET)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 127
Study: 28903957

Group type: EXPERIMENTAL
Intervention: Skewed protein distribution (10 g at breakfast, 20 g at lunch, and 60 g at dinner; n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Even protein distribution (30 g each at breakfast, lunch, and dinner; n = 21)
Number of subjects: 41
Study: 26141379

Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (cohort A)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (cohort B)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Control group (culture medium) (cohort A)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Control group (culture medium) (cohort B)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (younger group <38 years)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Control group (younger group <38 years)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (older group ≥38 years)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Control group (older group ≥38 years)
Number of subjects: 1186
Study: 23651767

Group type: EXPERIMENTAL
Intervention: Internet-based alcohol interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21491994

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 μg/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (1 tablet)
Number of subjects: 62
Study: 19922618

Group type: COMPARATOR
Intervention: Client information leaflet control condition (n = 32 OMs)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 5-minute simple structured advice (n = 32 OMs)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 20-minute brief lifestyle counselling delivered by an Alcohol Health Worker (n = 32 OMs)
Number of subjects: 480
Study: 16513449

Group type: EXPERIMENTAL
Intervention: Pomelo juice with cyclosporine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cranberry juice with cyclosporine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with cyclosporine
Number of subjects: 12
Study: 15299059

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT
Number of subjects: 20

Group type: COMPARATOR
Intervention: (18)F‐FDG PET alone
Number of subjects: 20
Study: 11228210

Group type: EXPERIMENTAL
Intervention: recombinant human FSH (r‐hFSH) 150 IU/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: highly purified urinary FSH (u‐hFSH HP) 150 IU/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (normal ovulation women)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both r‐hFSH and u‐hFSH
Number of subjects: 50
Study: 9347380

Group type: EXPERIMENTAL
Intervention: Mianserin (n = 13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Trazodone (n = 12)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 38
Study: 8102399

Group type: EXPERIMENTAL
Intervention: Olsalazine (30 mg/kg/day, max 2 g/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sulfasalazine (60 mg/kg/day, max 4 g/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 56
Study: 2967028

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: acebutolol 200 mg
Number of subjects: 10
Study: 29719884

Group type: EXPERIMENTAL
Intervention: Software-directed medication history
Number of subjects: 209

Group type: COMPARATOR
Intervention: Paper-based medication history
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 209
Study: 28594615

Group type: EXPERIMENTAL
Intervention: Tooth-brushing with concurrent suctioning technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouth-swabbing
Number of subjects: 0
Study: 26563599

Group type: EXPERIMENTAL
Intervention: 4th Edition Second Step® program combined with brief training on proactive classroom management
Number of subjects: 7300

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 7300
Study: 23507561

Group type: EXPERIMENTAL
Intervention: WebChoice eHealth application
Number of subjects: 103
Study: 21508856

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 20 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 40 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 80 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo (am) and 15 mg of olanzapine (pm) daily
Number of subjects: 0
Study: 19620593

Group type: EXPERIMENTAL
Intervention: Esophageal speech (ES)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Electrolaryngeal speech (EL)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pneumatic device speech (PD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tracheoesophageal speech (TE)
Number of subjects: 49
Study: 17380807

Group type: EXPERIMENTAL
Intervention: Metallic matrix and wooden wedge
Number of subjects: 23

Group type: COMPARATOR
Intervention: Polyester matrix and reflexive wedge
Number of subjects: 23
Study: 15067584

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11903414

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 9012279

Group type: EXPERIMENTAL
Intervention: Histamine H2-receptor antagonists in conventional dosages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prokinetic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole and lansoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study: 7951199

Group type: EXPERIMENTAL
Intervention: Interactive imagery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of BEER and 'alcoholic beverages' before study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of DOG and BEER
Number of subjects: 0
Study: 3301166

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment before feeding
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Feeding
Number of subjects: 6

Group type: COMPARATOR
Intervention: Indomethacin (oral dose 2h before measurement)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 6
Study: 31810563

Group type: EXPERIMENTAL
Intervention: Segmented Le Fort I osteotomy with alar cinch technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-segmented Le Fort I osteotomy with alar cinch technique
Number of subjects: 80
Study: 29127910

Group type: EXPERIMENTAL
Intervention: β‐d‐mannuronic acid
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 26202487

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 26
Study: 25633207

Group type: EXPERIMENTAL
Intervention: Adapted Diabetes Prevention Program (DPP) lifestyle intervention
Number of subjects: 89
Study: 23985436

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1450 ppm fluoride
Number of subjects: 331

Group type: COMPARATOR
Intervention: Dentifrice containing 1450 ppm fluoride (positive control)
Number of subjects: 331
Study: 20598453

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy and external‐beam radiotherapy
Number of subjects: 120
Study: 18669565

Group type: EXPERIMENTAL
Intervention: Open access articles
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Subscription access articles
Number of subjects: 1619
Study: 16630091

Group type: EXPERIMENTAL
Intervention: Magnesium l-lactate (504 mg elemental magnesium daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14681282

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg zinc sulphate daily for 6 days a week for 6 months)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 10618281

Group type: EXPERIMENTAL
Intervention: ANA enzyme immunoassay (EIA)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Rat liver and HEp-2
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Anti-ENA EIA
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Anti-dsDNA EIA
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Measurement of anti-Scl-70 and anti-Jo-1
Number of subjects: 460

Group type: COMPARATOR
Intervention: ANA EIA
Number of subjects: 460
Study: 8790093

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Partial RD not involving the fovea
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Partial RD involving the fovea
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall visual acuity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Extent of RD at 3 months
Number of subjects: 61
Study: 1636921

Group type: EXPERIMENTAL
Intervention: Tramadol and metamizole infusion (400 mg tramadol plus 5 g metamizole in 500 ml electrolyte solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol infusion (400 mg tramadol plus 10 ml placebo in 500 ml electrolyte solution) with ibuprofen suppositories (585.2 mg) preoperatively
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol and metamizole infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol infusion with ibuprofen suppositories
Number of subjects: 60
Study: 6199153

Group type: EXPERIMENTAL
Intervention: Clonidine (6 or 12 micrograms/kg/day for 2 weeks)
Number of subjects: 12
Study: 31187102

Group type: EXPERIMENTAL
Intervention: 30 mg/mL ketorolac tromethamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 29575339

Group type: EXPERIMENTAL
Intervention: Packaged Cognitive Behavior Therapy (PCBT)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Case management control treatment
Number of subjects: 403
Study: 27144937

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 20 mg thrice daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23124601

Group type: EXPERIMENTAL
Intervention: Posterior stabilized mobile TKA
Number of subjects: 69

Group type: COMPARATOR
Intervention: Posterior stabilized fixed TKA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with anterior knee pain
Number of subjects: 69
Study: 21699645

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/day)
Number of subjects: 8231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8231

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 8231
Study: 20121500

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg/day)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 17419222

Group type: EXPERIMENTAL
Intervention: Three-port technique
Number of subjects: 146

Group type: COMPARATOR
Intervention: Four-port technique
Number of subjects: 146
Study: 15540300

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 384

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 384
Study: 11498726

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD) drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced amino acid drink (Control)
Number of subjects: 0
Study: 9516029

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 750 microg per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 microg per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 375 microg per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 8062327

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b 3 million units three times a week for 24 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Responders (patients with improvement in serum alanine aminotransferase levels)
Number of subjects: 160
Study: 2920584

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (100 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Physiologic saline solution (Control)
Number of subjects: 96
Study: 807867

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 26
Study: 31331782

Group type: EXPERIMENTAL
Intervention: Elective Nodal Radiotherapy (ENRT)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Number of subjects: 506
Study: 27189038

Group type: EXPERIMENTAL
Intervention: Zinc (Zn)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Multivitamins (MV)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Zinc and Multivitamins (Zn + MV)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Zinc vs No Zinc
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Multivitamins vs No Multivitamins
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Treatment arms comparison
Number of subjects: 2400
Study: 25881614

Group type: EXPERIMENTAL
Intervention: DRV/r once-daily (800/100 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: DRV/r twice-daily (600/100 mg)
Number of subjects: 60
Study: 23809446

Group type: EXPERIMENTAL
Intervention: 12.0‐μg/h fentanyl patch for 72 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo patch and an infusion of 2.5‐mg/mL bupivacaine in a subacromial manner for 72 hours
Number of subjects: 60
Study: 22073764

Group type: EXPERIMENTAL
Intervention: Brief self-report measure of positive and negative core beliefs about God
Number of subjects: 0
Study: 18978485

Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15720929

Group type: EXPERIMENTAL
Intervention: Audit plus risk feedback
Number of subjects: 30345

Group type: COMPARATOR
Intervention: Audit only feedback
Number of subjects: 30345

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30345
Study: 11883990

Group type: EXPERIMENTAL
Intervention: Learning to control SCPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of SCPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control of SCPs
Number of subjects: 0
Study: 9470102

Group type: EXPERIMENTAL
Intervention: Lead Intervention program for lead reduction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Accident Intervention program
Number of subjects: 65
Study: 8561982

Group type: EXPERIMENTAL
Intervention: HIV vaccine trial participation
Number of subjects: 0
Study: 2131262

Group type: EXPERIMENTAL
Intervention: Conventional fiberendoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videoendoscopy
Number of subjects: 0
Study: 350264

Group type: EXPERIMENTAL
Intervention: Atenolol drops 4%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol-then-adrenaline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adrenaline drops 1%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combination of atenolol and adrenaline
Number of subjects: 12
Study: 30921609

Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at 4 Hz or 30 Hz based on EEG analysis, 5 days/week for 2 weeks followed by physical therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Number of subjects: 0
Study: 28599662

Group type: EXPERIMENTAL
Intervention: Peptamen® AF (modified enteral diet rich in proteins, medium chain triglycerides, and fish oil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isosource® Energy (standard diet)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Peptamen® AF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isosource® Energy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diarrhea
Number of subjects: 90
Study: 26152940

Group type: EXPERIMENTAL
Intervention: Ophthalmic solution containing an allergen (CPT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 159
Study: 23550857

Group type: EXPERIMENTAL
Intervention: 200 μg sublingual misoprostol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 5 IU i.m. oxytocin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 104
Study: 21860356

Group type: EXPERIMENTAL
Intervention: HSV-2 infection
Number of subjects: 1836

Group type: COMPARATOR
Intervention: HSV-2 infection in placebo recipients
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Past HSV-2 infection
Number of subjects: 1836
Study: 19249425

Group type: EXPERIMENTAL
Intervention: Aspirin plus coumarin (adjunctive anticoagulation)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Aspirin alone (control)
Number of subjects: 251
Study: 17188780

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 96
Study: 15492433

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide-erythromycin gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metronidazole gel
Number of subjects: 56
Study: 11560210

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenously for 72 hours
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 21
Study: 9563813

Group type: EXPERIMENTAL
Intervention: Multi modal day program
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 7943586

Group type: EXPERIMENTAL
Intervention: Resection with primary anastomosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ileocolostomies
Number of subjects: 60
Study: 3207549

Group type: EXPERIMENTAL
Intervention: Bilateral ilioinguinal nerve blockade using 0.5% plain bupivacaine 10 ml to each side
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no nerve blockade)
Number of subjects: 13
Study: 29427701

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day; n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day; n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40
Study: 27435286

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 67
Study: 25703737

Group type: EXPERIMENTAL
Intervention: Unsupervised video-enhanced feedback (UVF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Individualized video feedback (IVF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard lecture feedback
Number of subjects: 32
Study: 23154449

Group type: EXPERIMENTAL
Intervention: CPAP withdrawal (subtherapeutic CPAP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Continuing therapeutic CPAP
Number of subjects: 41